Slide 1: Company overview
Company overview NOVEMBER 2024
Slide 2: Innate Pharma snapshot
Innate Pharma snapshot Global, clinical-stage oncology-focused biotech company. Scientific excellence in the field of innate immunity with expertise in Natural Killer (NK) cell biology and antibody engineering. Focused pipeline of antibodies, including several potentially first-in-class clinical and
Slide 3: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 4: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Pre-Clinical Phase 1 Phase 2 Phase 3 IPH67 IPH5301 (CD73) Lacutamab (KIR3DL2) Monalizumab (NKG2A) Undisclosed, solid tumor Solid tumors CTCL Unresectable Stg III NSCLC IPH81 IPH6501 (CD20-IL2v) Lacutamab (KIR3DL2) Undisclosed Target B-NHL PTCL Ot
Slide 5: Scientific innovation drives our strategy
Scientific innovation drives our strategy Leveraging our expertise in innate immunity and antibody engineering to develop novel, first-in-class therapies for cancer, advancing a diverse pipeline of proprietary and partnered assets with major biopharma companies Lacutamab ANKET® & ADC Monalizumab Pha
Slide 6: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts Delivering across our strategic objectives • Lacutamab TELLOMAK | end of Phase 2 FDA interaction • Lacutamab PTCL | Phase 2 Data • IPH5301 (CD73) | Phase 1 data at ESMO 2024 Proprietary • IPH6501 ANKET® (CD20 IL2v) | Phase 1 progress • IPH6501 ANKET® (CD20 IL2v) | Pha
Slide 7: Building a robust pipeline on strong basics
Building a robust pipeline on strong basics Validated Strong track Robust Science record of pipeline collaborations 7 drug candidates in clinical stage Including 3 proprietary and 4 in partnerships 7
Slide 8: Lacutamab: Drive near-term value
Lacutamab Drive near-term value 8
Slide 9: Lacutamab: lead proprietary asset
LACUTAMAB Lacutamab: lead proprietary asset First-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody Lacutamab under development for the treatment of various forms of T-cell lymphomas (TCL) and Peripheral T Cell Lymphomas (PTCL). Compelling Phase 1 data in Sezary syndrome (SS), published
Slide 10: Lacutamab | Clinical Trials
LACUTAMAB Lacutamab | Clinical Trials A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 Cutaneous T cell lymphoma TELLOMAK Phase 2 Trial Sézary syndrome Sézary syndrome N=56 Phase 2 ~90% KIR3DL2 Minimum of 2 prior therapies, including mogamulizumab 2025 expression ≥1% Mycos
Slide 11: Lacutamab | Mycosis fungoides efficacy results from Phase 2 TELLOMAK
LACUTAMAB Lacutamab | Mycosis fungoides efficacy results from Phase 2 TELLOMAK Best Overall Response by KIR3DL2 Expression Level KIR3DL2 ≥ 1% (N=48) Patient characteristics (N=107) 4 median lines of prior therapy 11.8 months median follow up Efficacy results Olsen 2011 Global ORR % (95%CI) 16.8% (10
Slide 12: Lacutamab | Sézary syndrome Phase 2 data
LACUTAMAB Lacutamab | Sézary syndrome Phase 2 data Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial Patient characteristics Data cutoff: May 1, 2023 56 post mogamulizumab patients with advanced, highly refractory and heavily pre-treated dise
Slide 13: TELLOMAK data support lacutamab as a potential new SoC in MF & SS
LACUTAMAB TELLOMAK data support lacutamab as a potential new SoC in MF & SS with opportunity across patient subgroups and earlier lines of therapy KIR3DL2 enriched population Expansion All comers Line Expansion ~ 1,500 patients ~3,500 patients ~5,000 patients KIR3DL2 KIR3DL2 All Comers All Comers <1
Slide 14: Initiating data-driven strategy in PTCL
LACUTAMAB Initiating data-driven strategy in PTCL Now Next steps RELAPSED SETTING FRONTLINE Highest unmet medical need Driven by data in the relapsed setting to advance Combination with GemOx into earlier lines (LYSA-sponsored Phase 2 KILT study) Combination with CHOP SOC: Standard of care, CHOP: Cy
Slide 15: ANKET & ADC: Advance our innovative R&D pipeline
ANKET® & ADC Advance our innovative R&D pipeline 15
Slide 16: Proprietary NK cell engager platform
ANKET® Proprietary NK cell engager platform Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46. Provides proliferation and activation signals targeted to NK cells. Demonstrates better anti-tumor efficacy than approved benchmar
Slide 17: ANKET, a differentiated technology in the NK landscape
ANKET® ANKET®, a differentiated technology in the NK landscape CHECKPOINT INHIBITORS NKp46 NK CELL ENGAGERS NK cells CD20-IL2v IPH6501 CD16 HALLMARKS OF NK CELL TUMOR IMMUNITY BCMA NK and myeloid cells SAR’514, IPH6401 CD123 • Natural recognition of cancer cells, as the first line of the LILRB1 EGFR
Slide 18: Multiple ANKET programs targeting hematological malignancies and solid tumors
ANKET® Multiple ANKET® programs targeting hematological malignancies and solid tumors Growing clinical pipeline SAR’579 / IPH6101 (CD123) Phase 1 / 2 SAR443579 progress to Ph2 in R/R AML SAR’514 / IPH6401 (BCMA) Phase 1 / 2 New Phase 1/2 in 1L AML in combination with azacytidin + venetoclax IPH6501
Slide 19: SAR'579 / IPH6101 promising preliminary single agent clinical activity in R/R AML
ANKET® SAR'579 / IPH6101 promising preliminary single agent clinical activity in R/R AML SAR’579 (SAR443579) / IPH6101 is a trifunctional anti-CD123 NKp46-CD16 NK cell engager PHASE 1 / 2 underway in R/R AML, B-cell ALL or HR MDS Individual Patient Responses per Investigator: Dose-Escalation Phase E
Slide 20: IPH6501, a novel CD20-targeting tetra-specific NK cell engager
ANKET® IPH6501, a novel CD20-targeting tetra-specific natural killer cell engager from ANKET® platform, has started clinical study in B-cell malignancies Phase 1/2 first-in-human, multicenter, in Patients With Relapsed and/or CD20 Refractory Non-Hodgkin Lymphoma Anti- CD20 NCT06088654 First patient
Slide 21: Preclinical data support evaluation of IPH6501 in B-NHL
ANKET® Preclinical data support evaluation of IPH6501 in relapsed or refractory B-NHL subtypes and post-CAR-T therapy NKp46 provides a key advantage for IPH6501 has potential across subtypes of B-NHL, IPH6501 over CD20-targeting Abs including in post CAR-T setting FL FL Killing by NK cells lymph nod
Slide 22: IPH6501 potential path forward
ANKET® IPH6501 potential path forward Generate safety data and preliminary signals of activity in 2025 CD20+ B-NHL Confirm activity signal with dose optimized in CD20+ B-NHL 2026 & select B-NHL subtypes for expansion cohorts 2027 & Expansion study in selected B-NHL subtypes beyond & explore combinat
Slide 23: Developing differentiated ADC assets to the clinic
ADC We are leveraging our antibody expertise by developing differentiated ADCs asset to the clinic ADC Research pipeline – Lead asset at pre-IND stage IPH4502 (Nectin-4) IND cleared IPH43 (MICA/B) Phase 1 Research Target (Tumor antigen) Research Research 23
Slide 24: IPH4502 is a novel and differentiated Nectin-4 DAR8 exatecan ADC
ADC IPH4502 is a novel and differentiated Nectin-4 DAR8 exatecan ADC Progress towards IND in 2024 Payload Exatecan, Binder a Topoisomerase I inhibitor • Active in EV/MMAE-resistant models Proprietary humanized • Higher Bystander Effect than EV, anti-Nectin-4 Antibody leading to stronger activity in
Slide 25: Nectin-4 expression on a broad panel of indications beyond bladder cancer
ADC Our aim: target Nectin-4 on a broad panel of indications on top of bladder cancer OPPORTUNITIES 100 No Nectin-4 drug approved • PADCEV (enfortumab vedotin, EV) is approved % of Nectin-4 expressing 80 in bladder where expression of Nectin-4 is the tumor samples highest 60 • Relapses are frequentl
Slide 26: IPH4502, a novel and differentiated exatecan-based ADC in Nectin-4 tumors
ADC IPH4502, a novel and differentiated exatecan-based ADC in Nectin-4 expressing tumors Nectin-4+ cells Nectin-4+ cells Nectin-4 KO cells + Nectin-4 KO cells Tumor volume (mm3) In vivo bystander killing Address heterogeneous Nectin-4 expression Efficacy in model of EV acquired resistance Address po
Slide 27: IPH4502 potential path forward
ADC IPH4502 potential path forward 2024 IND and generate preliminary Phase 1 safety data 2025 Establish preliminary activity signal in Nectin-4 expressing tumor types 2026 with low and high expression levels Beyond Dose optimization and exploration of combination in expansion cohorts Data will infor
Slide 28: Adenosine Pathway: IPH5201 (anti-CD39) and IPH5301 (anti-CD73)
ADENOSINE Adenosine Pathway: IPH5201 (anti-CD39) and IPH5301 (anti-CD73) IPH5301 Perrot et al. 2019 Cell Reports - Allard B. et al. Immunol.l Rev.. 2017 - Vigano S. et al. Front. Immunol. 2019 - Kepp O. et al. EMBO J. 2021 - ATP : adenosine triphosphate - AMP : adenosine monophosphate 28
Slide 29: IPH5201: Phase 2 clinical trial MATISSE initiated
IPH5201 IPH5201: Phase 2 clinical trial MATISSE initiated Phase 1 in advanced solid tumors Preclinical data Phase 2 trial MATISSE ongoing completed (sponsor: AstraZeneca) Best change in tumor size from baseline Non small cell lung cancer (NSCLC) IPH5201 monotherapy IPH5201 + durvalumab Neoadjuvant c
Slide 30: IPH5301: Phase 1 clinical trial CHANCES ongoing
IPH5301 IPH5301: Phase 1 clinical trial ISS CHANCES ongoing Preclinical data Phase 1 CHANCES IST ongoing (sponsor: IPC) IPH5301 epitope translates into superior blocking capacity on both membrane and soluble CD73 and superior T cell activation; IPH5301 has the potential to enhance PD-1 efficacy Adva
Slide 31: Build a sustainable business through partnerships
Build a sustainable business through partnerships 31
Slide 32: Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams
MONALIZUMAB Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams Late-stage clinical trial highlights Monalizumab blocks the NKG2A AstraZeneca initiated Phase 3 trial, PACIFIC-9 inhibitory receptor on both NK cells and with monalizumab + durvalumab in patients with cytoto
Slide 33: Monalizumab development in lung cancer
MONALIZUMAB Monalizumab development in lung cancer Phase 2 NeoCOAST Phase 2 COAST Clinical Stg I-IIIA NSCLC Unresect. Stg III NSCLC monalizumab + durvalumab monalizumab + durvalumab studies in In progress In progress Phase 2 NeoCOAST-2 Phase 3 PACIFIC-9 NSCLC 999 pts Stg II-IIIA NSCLC Unresect. Stg
Slide 34: Strategic partnership with AstraZeneca
MONALIZUMAB Strategic partnership with AstraZeneca Monalizumab Amounts received Total amount of the agreement: 1.275 billion US$ Total milestones Milestone Initial payments 250 100 payments Development and regulatory 50 50 400 In US$ million Commercialization 425 Royalties Outside Europe Europe on s
Slide 35: Strategic partnership with AstraZeneca: IPH5201
IPH5201 Strategic partnership with AstraZeneca IPH5201 Milestone payments $60m Potential total amount of the Already received agreement Including $5 million in milestone payment for the launch of the MATISSE Phase 2 trial. $885 million Royalties on sales Outside Europe AstraZeneca will record all sa
Slide 36: Strategic partnership between Sanofi and Innate
ANKET® Strategic partnership between Sanofi and Innate Four molecules licensed to Sanofi plus one undisclosed target remaining under option IPH6101/SAR’579 IPH6401/SAR’514 IPH62 OPTION Ongoing CD123 BCMA B7-H3 Target undisclosed programs Phase 1 / 2 in AML Phase 1 / 2 in Multiple Myeloma Research Pa
Slide 37: Key takeaways
B innate pharma Key takeaways 37
Slide 38: Key Takeaways
Key Takeaways Create value for patients and shareholders Clinical stage company with growing differentiated first-in-class pipeline • LACUTAMAB • Encouraging FDA feedback on regulatory pathway • EXPAND ANKET® CLINICAL PORTFOLIO – LEAD IN HEMATOLOGY INDICATIONS • Phase 1/2 clinical trial underway wit
Slide 39: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts Delivering across our strategic objectives • Lacutamab TELLOMAK | Phase 2 FDA interaction • Lacutamab TELLOMAK | Next steps completed • Lacutamab PTCL | Phase 2 Data • IPH5301 (CD73) | Phase 1 data at ESMO 2024 Proprietary • IPH6501 ANKET® (CD20 IL2v) | Phase 1 progre
Slide 40: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA